Loading organizations...
Based in Newton, Massachusetts, Dash Bio is a biotechnology service provider that utilizes artificial intelligence, robotics, and proprietary software to accelerate clinical bioanalysis for drug development. The company addresses operational inefficiencies in the pharmaceutical and biotech sectors by delivering assay results for clinical trials and GLP studies up to ten times faster than standard industry averages. Operating with a workforce of over 20 employees, the enterprise has raised $17.5 million in total venture capital funding across multiple seed financing rounds to scale its automated laboratory operations. The organization's early financial backers include a syndicate of prominent venture capital firms, featuring lead investor Freestyle Capital alongside Swift Ventures, LifeX Ventures, Drive Capital, and Cybernetix Ventures. Dash Bio was officially founded in 2024 by former Moderna executives Dave Johnson and Ander Tallett, alongside Rootpath co-founder Ely Porter.
Dash Bio has raised $29.0M across 3 funding rounds.
Dash Bio has raised $29.0M in total across 3 funding rounds.
Dash Bio is a technology-driven company that builds a fully automated platform combining AI, robotics, and integrated software to transform clinical bioanalysis, a critical step in drug development. Their platform delivers bioanalytical testing for clinical trials up to 10 times faster than traditional methods while maintaining or improving assay quality and compliance with Good Laboratory Practice (GLP) standards. Dash Bio serves biopharmaceutical companies, including growth-stage biotech firms and large pharmaceutical companies, by accelerating the drug development process, reducing costs, and improving data reliability across preclinical and clinical trial stages[1][2][4][5].
Founded by a team with deep expertise in biotechnology, automation, and AI, Dash Bio’s leadership includes CEO Dave Johnson (formerly Chief Data and AI Officer at Moderna), COO Ander Tallett (with experience leading enterprise systems at Moderna and Resilience), and CSO Ely Porter (co-founder and CTO of Rootpath). The idea emerged from recognizing the bottlenecks in traditional bioanalysis workflows, which are often manual, slow, and error-prone. Early traction came from building a technology-first, fully integrated bioanalysis lab designed from the ground up to automate and accelerate the entire workflow, differentiating Dash Bio from legacy contract research organizations (CROs)[1][2][4].
Dash Bio rides the convergence of synthetic biology, automation, AI, and cloud software to address critical inefficiencies in drug development. The timing is crucial as biopharma increasingly demands faster, more reproducible, and cost-effective bioanalytical testing to keep pace with rapid innovation in therapeutics. Market forces such as rising R&D costs, demand for personalized medicine, and regulatory pressures favor automation and digital transformation. Dash Bio’s technology-first approach positions it as a catalyst for industry-wide change, potentially reshaping how bioanalysis is conducted and accelerating the delivery of new medicines to patients[1][3][4].
Looking ahead, Dash Bio aims to scale its automated clinical bioanalysis lab and expand its assay portfolio beyond ELISA, LC-MS, and qPCR to cover more modalities and services. The company plans to deepen integration of AI and automation across the drug development lifecycle, potentially addressing other bottlenecks beyond bioanalysis. As the biotech industry embraces digital transformation, Dash Bio’s influence is likely to grow, driving faster, more reliable drug development and setting new standards for technology-enabled bioanalysis[2][4]. Their success will depend on continued innovation, expanding customer adoption, and navigating regulatory landscapes while maintaining high-quality standards.
Dash Bio has raised $29.0M across 3 funding rounds. Most recently, it raised $11.0M Other Equity in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 23, 2025 | $11M Venture Round | Ariel Winton | Cybernetix Ventures, Drive Capital, Freestyle Capital, LifeX Ventures, Swift Ventures | Announced |
| Jul 1, 2025 | $11M Seed | The Aligned Fund | Kindred Capital VC, Swift Ventures, True Ventures, Mario Götze, Veeral Mehta, Cybernetix Ventures, Drive Capital, Freestyle Capital, LifeX Ventures | Announced |
| Oct 1, 2024 | $7M Seed | Maria Palma | Kindred Capital VC, Swift Ventures, True Ventures, Mario Götze, Nico Rosberg, Veeral Mehta, LifeX Ventures | Announced |
Dash Bio has raised $29.0M in total across 3 funding rounds.
Dash Bio's investors include Ariel Winton, Cybernetix Ventures, Drive Capital, Freestyle Capital, LifeX Ventures, Swift Ventures, The Aligned Fund, Kindred Capital VC, True Ventures, Mario Götze, Veeral Mehta, Maria Palma.